

Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe's National Antiretroviral Therapy Programme between 2012 and 2015

Richard Makurumidze^{1,4,6¶}, Tsitsi Mutasa-Apollo^{2¶}, Tom Decroo^{4,5}, Regis C. Choto², Kudakwashe C. Takarinda^{2,7}, Janet Dzangare², Lutgarde Lynen⁴, Wim Van Damme^{4,6}, James Hakim¹, Tapuwa Magure³, Owen Mugurungi², Simbarashe Rusakaniko¹

1. College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe
2. AIDS & TB Unit, Ministry of Health & Child Care, Harare, Zimbabwe
3. National AIDS Council, Harare, Zimbabwe
4. Institute of Tropical Medicine, Antwerp, Belgium
5. Research Foundation of Flanders, Brussels, Belgium
6. Gerontology, Faculty of Medicine & Pharmacy, Free University of Brussels (VUB), Brussels, Belgium
7. International Union Against Tuberculosis and Lung Disease, Paris, France.

*** Corresponding Author:** Email: rmakurumidze@ext.itg.be (RM)

¶RM and TA are joint first authors.

Abstract

Background

The last evaluation to assess outcomes for patients receiving antiretroviral therapy (ART) through the Zimbabwe public sector was conducted in 2011, covering the 2007-2010 cohorts. The reported retention at 6, 12, 24 and 36 months were 90.7%, 78.1%, 68.8% and 64.4%, respectively. We report findings of a follow up evaluation for the 2012-2015 cohorts to assess the implementation & impact of recommendations from this prior evaluation.

Methods

A nationwide retrospective study was conducted in 2016. Multi-stage proportional sampling was used to select health facilities and study participants records. The data extracted from patient manual records included demographic, baseline clinical characteristics and patient outcomes (active on treatment, died, transferred out, stopped ART and lost to follow-up (LFTU)) at 6, 12, 24 and 36 months. The data were analysed using Stata/IC 14.2. Retention was estimated using survival analysis. The predictors associated with attrition were determined using a multivariate Cox regression model.

Results

A total of 3,810 participants were recruited in the study. The median age in years was 35 (IQR: 28-42). Overall, retention increased to 92.4%, 86.5%, 79.2% and 74.4% at 6, 12, 24 and 36 months respectively. LFTU accounted for 98% of attrition. Being an adolescent or a young adult (aHR 1.41; 95%CI:1.14-1.74), receiving care at primary health care facility (aHR 1.23; 95%CI:1.01-1.49), having initiated ART between 2014-2015 (aHR 1.45; 95%CI:1.24-1.69), having WHO Stage 4 (aHR 2.06; 95%CI:1.51-2.81) and impaired functional status (aHR 1.24; 95%CI:1.04-1.49) predicted attrition.

Conclusion

The overall retention was higher in comparison to the previous 2007–2010 evaluation. Further studies to understand why attrition was found to be higher at primary health care facilities are warranted. Implementation of strategies for managing patients with advanced HIV disease, differentiated care for adolescents and young adults and tracking of LFTU should be prioritised to further improve retention.

Key words

ART outcomes, implementation, low resource setting, differentiated care, Zimbabwe

Introduction

Globally by the end of 2018, there were 37.9 million [32.7 million–44.0 million] people living with HIV (PLHIV) with 61% of these residing in Eastern and Southern Africa (ESA) [1]. Over the past two to three decades, investments in the global HIV response have achieved unprecedented results with the number of new HIV infections significantly reduced from 2.9 million [2.3 million–3.8 million] in 1997 to 1.7 million [1.6 million–2.3 million] new infections by 2018 and 23.3 million PLHIV put on treatment globally [1]. Between 2010 and 2018 new HIV infections and deaths decreased by 16% and 33%, respectively [2]. Despite these remarkable achievements, patient attrition and losses to follow-up (LTFU) still remain legitimate threats to the long-term success of antiretroviral therapy (ART) scale up [3].

PLHIV on ART who are not retained in care are at increased risk of developing drug resistance and dying [4]. Based on a systematic review of several studies that have been conducted in low resource settings, key predictors of high attrition include patients with advanced HIV-disease progression [marked by body mass index (BMI) <18 kg/m², baseline CD4 counts <200 cells/mL, World Health Organisation (WHO) Stage - III and IV, poorer level of functionality], male sex, younger age and having lower levels of education [5]. Early ART initiation as measured by shorter time duration between HIV testing and ART initiation has been shown to reduce risk of attrition[6,7]. Other studies have however shown that those who initiate ART at a higher baseline CD4 may also be prone to attrition [8,9].

Numerous studies assessed attrition and the effect of different initiatives on treatment outcomes at selected health facilities in resource-limited settings [7,8,10–12]. They mainly reflect the experience of academic, standalone, donor supported or private institutions that generally have better data collection systems, are well financed and have better human resources for health,

which may not be generalizable. In scenarios where outcomes for routine programmes have been reported, evaluations have often been regional, limited to a few facilities or targeting only a specific subpopulation of the HIV cohorts (children, adolescents or adults) [6,13–17]. There is paucity of data demonstrating treatment outcomes and impact of ART at a national level in many resource-limited settings. Periodic national treatment outcome evaluations provide information needed for targeted interventions that will allow national HIV programmes to achieve the ambitious UNAIDS 3rd 90 by 2020.

Zimbabwe started rolling out ART in the public health system in 2004 in 5 pilot facilities. Since then, there has been significant scale-up with more than 1500 health institutions offering ART by the end of 2017 [18]. This rapid scale-up has been mostly attributed to the rapid adaptation of the WHO HIV guidelines and the widespread decentralization of comprehensive HIV services which was supported by health care worker task-shifting policies and significant investments in training, supportive supervision and clinical mentoring [19]. Funding from the Government of Zimbabwe, Global Fund for AIDS, Tuberculosis, and Malaria (GFATM), the United States of America President’s Emergency Plan for AIDS Relief (PEPFAR) and other donors supported the scale-up the program.

An evaluation of the Zimbabwe national ART programme, which only included adults (> 15 years) living with HIV started on ART between 2007-2010, reported 90.7%, 78.1%, 68.8% and 64.4% retention at 6, 12, 24 and 36 months, respectively [17]. These findings mirrored treatment outcomes in other parts of sub-Saharan Africa and recommendations given included strengthening earlier diagnosis and linkages to treatment; further decentralization of comprehensive HIV services to improve ART coverage and adaptation of innovative strategies

aiming at improving patient retention (adherence clubs, food supplementation and mobile short messages service (SMS) reminders) [17].

In our study, we report results of a 2016 follow-up evaluation of treatment outcomes of the Zimbabwe National ART Programme, conducted among individuals who started ART between 2012-2015, prior to the implementation of the HIV ‘Treat All’ policy. This nationwide follow-up evaluation therefore assessed the impact of the interventions implemented since the first evaluation. The assessment was expanded to include children and adolescents and was aiming to determine retention and estimate risk factors associated with attrition among the different population target groups.

Material & Methods

Study design

A retrospective cohort analysis was undertaken among children, adolescents and adults living with HIV who started ART in Zimbabwe between October 2012 and January 2015.

Study setting

The study was conducted at selected public health institutions across all the country's 10 provinces. Zimbabwe has a population of around 13 million [20]. The country has a generalised HIV epidemic and prevalence has continued to hover between 13 % and 16 % for the past decade. Currently there are about 1.4 million PLHIV of which 1.0 million (71%) were on (ART) by December 2018 [18]. Since 2004 the country has adopted all the successive changes in the WHO recommendations to start ART. Patients were eligible to start ART when they had a CD4 count <350 cells/mL in 2010, CD4 <500 cells/mL in 2013 and since 2016, patients are eligible regardless of their CD4 count (Treat All). The country has made significant progress towards achieving the 90-90-90 targets. In a recent survey, 74.2% reported knowing their HIV status; 86.8% self-reported current use of ART and among those who self-reported current use of ART, 86.5 % were virally suppressed [21].

During the period between 2011 and 2015, the Zimbabwe National AIDS Strategic Plan II (ZNASP-II) 2011-15 was developed to guide the scale-up of HIV care and treatment services towards universal access [22]. In 2013, the country adopted the 2013 WHO guidelines which recommended the CD4 < 500 cells/mL threshold for ART initiation. A 'test and treat' approach was adopted for all HIV-positive children under 5 years, TB/HIV co-infected, HBV/HIV co-infected, the HIV-positive partner in HIV sero-discordant relationship and pregnant and

breastfeeding mothers (Option B+). The preferred first-line regimen for adults, adolescents, and older children was changed from stavudine, lamivudine and nevirapine (d4T/3TC/NVP) to a once-daily pill of tenofovir, lamivudine and efavirenz (TDF/3TC/EFV) with zidovudine and nevirapine as alternatives for TDF and EFV respectively. After ART initiation stable patients were reviewed every 3 months and drugs were dispensed directly from the health facilities. Monitoring was mainly clinical (weight, WHO clinical stage and assessment of opportunistic infections) at every visit, complemented with laboratory tests (CD4 testing) every 6 months. Compared to the previous period access to CD4 testing improved significantly. By the end of 2015, laboratory based CD4 testing was available in each of the 63 districts as compared to 47 in 2009 [23]. On top of laboratory based CD4 testing, more than 265 point of care (POC) CD4 testing devices were procured and distributed throughout the country mainly to support the roll out of Option B+ [24]. Blood collection and transportation systems were put in place to support facilities without access to CD4 testing. Routine viral load testing was not available in the public sector and there was limited access to targeted viral load testing for patients with suspected treatment failure. The monitoring and evaluation system was mainly paper based. A few high-volume facilities started to implement an electronic patient monitoring system (ePMS) which operated concurrently with the usual paper-based system.

Sample size and sampling criteria

A minimum sample of 4000 patient charts was required to estimate 12-month ART retention (the outcome of interest), after assuming: 50% ART retention at 12 months after initiation, 20% of charts would be missing, a margin of error of 5% and a design effect of 2.0. For logistical and financially feasibility purposes, sampling was restricted to 1,389 ART sites across all 10 provinces that were supporting ≥ 50 HIV-positive clients on ART for at least 12 months by January 2016. The sites were stratified into seven strata according to their patient volumes

receiving ART care and ordered by province and district within each stratum. From these, 70 (5%) ART sites were sampled using a probability proportional to size sampling criteria based on client volumes receiving ART at each site. At the sampled sites, a line-listing was generated in Excel for all HIV positive children, adolescents, adults and pregnant women initiated on ART at the sampled sites between 1 October 2012 and 31 January 2015 using their unique ART numbers obtained from the facility ART register. Following this, the required number of patient ART care booklets were randomly selected without replacement according to their stratum based on random schedule generator in Stata. If a selected ART care booklet was not traceable, the next record was traced until the required sample size by site was reached

Study variables and treatment outcomes

The data collected included demographics (age, sex and marital status), clinical and programmatic variables. Baseline clinical parameters collected at point of ART initiation included WHO stage, functional status and pregnancy. Programmatic data collected included level of care, date of HIV testing, date of enrolment and date of ART initiation. Date of last clinic visit, date of next scheduled clinic visit and date of transfer-out/death/stopping ART were also collected and used to determine ART outcomes (i.e. active on treatment, LTFU, dead, transferred out and stopped ART). The date the patient outcome was ascertained was also collected. Patients were considered LTFU if they were more than 180 days without visit at the clinic on the date of data abstraction.

Data Collection Procedures

Ten teams of three data abstractors collected the data using a structured tool. The data

abstractors underwent a 5-day training programme to acquaint them with study tools and study procedures. Data collection tools were piloted to identify weaknesses which then were rectified. The primary source document for the study was the patient manual medical records (Patient OI/ART Booklets) being kept at the health institution. Other sources to complement or validate the information included the different registers and interviews with at least one experienced health care worker at each sampled site. Data was collected using Open Data Kit (ODK) software on Android devices. Data was downloaded at regular intervals for cleaning, quality control checks, merging and backing up. Data from a sample of 10% of the selected charts was re-abstracted as a quality control check measure. Discrepancies were addressed by both the team leader and data abstractors.

Data Analysis

The data were analysed using Stata/IC 14.2 [25]. The primary outcome was attrition, and this was defined as either being dead, LTFU or stopped ART. A Cox proportional hazard model was used to compute crude and adjusted hazard ratios and their 95% confidence intervals estimating the association between explanatory variables and attrition. Time to attrition was calculated as the time between the date of ART initiation and the date of outcome or last patient clinic visit. Those active on ART and transferred out were censored on the date of data abstraction and the date they were transferred out. Kaplan–Meier techniques were used to estimate retention on ART at 6, 12, 24 and 36 months. The retention at 6, 12, 24 and 36 months for adults (> 15years) was compared with the prior evaluation and two-sample test of proportions was used to assess if there was a difference. The log rank test was used to assess if differences between survival curves were statistically significant. A hierarchical approach was employed where all variables associated with P-value <0.1 in the univariable were included

initially in the multivariable model. A stepwise backward elimination until all remaining variables were significantly associated with attrition (p-value < 0.05).

Ethical Considerations

The evaluation protocol received ethics approval from Medical Research Council of Zimbabwe (MRCZ/A/2033). The protocol was also sanctioned by the MoHCC. Confidentiality and anonymity of ART clients was protected use their unique ART numbers as no names were abstracted. Permission to conduct the evaluation was sought at various levels of the tiered health delivery system. All data abstractors signed confidentiality forms.

Results

A total of 3,993 (99.8%) records were abstracted out of a target of 4,000. On data cleaning 3,810 (95.4%) records were found to be of quality standard for the analysis (Fig 1)

Fig 1. Study Population

Of 3,810 patients included, 38.7% and 48.6% started ART in 2013 and 2014, respectively, and 59.4% were female. The median age in years was 35 [interquartile range (IQR):28-42]. Most patients were adults (71.8 %), married (55.8%), and had a normal functional status (73.4%). Few (3.1%) were in WHO stage IV, and 27.1% started ART at a primary health care (PHC) facility. Among women of child bearing age 10.4% reported to be pregnant at time of ART initiation, 5.5% of the total study population (Table1).

Table 1. Baseline characteristics of 3810 patients who started ART between 2012-2015, in Zimbabwe

	N	(%)
Total	3810	100.0
Year of ART initiation		
2012	289	(7.6)
2013	1476	(38.7)
2014	1850	(48.6)
2015	195	(5.1)
Sex		
Female	2262	(59.4)
Male	1548	(40.6)
Median Age (N=3700) (IQR)	35 (28 - 42)	
Age groups		
Children (0-15 years)	254	(6.7)
Adolescents & young adults (15-24years)	385	(10.1)
Adults (25-49 years)	2735	(71.8)
Elderly (>=50 years)	424	(11.1)
Missing	12	(0.3)
Pregnancy at ART initiation		
Confirmed	208	(5.5)
Not confirmed	3602	(94.5)
Marital status of patient		
Single & divorced	863	(22.7)
Married	2125	(55.8)
Widowed	434	(11.4)

N/A Child	318	(8.3)
Missing	70	(1.8)
Baseline Functional Status		
Impaired	811	(21.3)
Normal	2796	(73.4)
Missing	203	(5.3)
Baseline WHO Stage		
WHO Stage I	821	(21.5)
WHO Stage II	1245	(32.7)
WHO Stage III	1447	(38.0)
WHO Stage IV	120	(3.1)
Unknown	177	(4.6)
Level of Care		
Central Hospital	888	(23.3)
Provincial Hospital	341	(9.0)
Mission/District Hospitals	1549	(40.7)
Primary Health Care facilities	1032	(27.1)

N - Number of observations, ART - Antiretroviral Therapy,
IQR - Interquartile Range, N/A - Not applicable, WHO -
World Health Organisation,

Fig 2 shows that the proportion of patients receiving ART at PHC facilities increased gradually from 21.6% in 2012 to 34.5% in 2015.

Fig 2. Level of care where the 3,810 patients started ART between 2012-2015, in Zimbabwe

Fig 3 shows that retention was significantly lower among patients who started ART between 2014-2015 as compared to those who started between 2012-2013 period (log-rank test: $p < 0.001$).

Fig 3. Comparison of retention rates of 3,810 patients who started antiretroviral therapy between 2012-2013 and 2014-2015 in Zimbabwe

Overall, retention at 6, 12, 24 and 36 months was 92.4%, 86.5%, 79.2% and 74.4%, respectively. Table 2 shows a comparison between adult patients who started ART between 2007-2010 and 2012-2015. Retention at 6, 12, 24 and 36 months was 1.4%, 10.0%, 14.3% and 14.5% higher among patients who started between 2012-2015. Differences were statistically significant except at 6 months.

Table 2. Retention in care of patients who started antiretroviral therapy between 2007-2010 and 2012-2015 in Zimbabwe

	Months since ART initiation	2012-2015 Evaluation			2007-2010 Evaluation			Difference		
		N	Retention (%)	95% CI	N	Retention (%)	95% CI	%	95%CI	^a P value
Overall	6	3476	92.4	(91.5 – 93.2)						
	12	3066	86.5	(85.3 – 87.5)						
	24	1427	79.2	(77.7 – 80.6)						
	36	222	74.4	(72.5 – 76.1)						
Children < 15 years	6	250	97.3	(94.4 – 98.7)						
	12	230	94.2	(90.5 – 96.4)						
	24	114	86.3	(81.0 – 90.2)						
	36	17	82.3	(75.5 – 87.4)						
Adults > 15 years	6	3222	92.0	(91.1 – 92.9)	3739	90.7	(86.1 – 93.8)	1.4	(-0.02 – 2.6)	0.06
	12	2832	85.9	(84.7 – 87.0)	3641	78.1	(67.7 – 84.7)	10.0	(5.9 – 10.0)	<0.001
	24	1311	78.7	(77.1 – 80.1)	2003	68.8	(58.5 – 77.5)	14.3	(6.9 – 12.9)	<0.001
	36	204	73.7	(71.8 – 75.6)	806	64.4	(55.7 – 72.3)	14.5	(2.4 – 16.2)	<0.001

^aTwo-sample test of proportions

257 Over 6,508 years of patient follow up; 77.4% were active on treatment, 2.4% transferred out and 20.2% were lost through attrition (LTFU 19.8 %,
258 and died 0.4%) The median follow-up time per patient was 1.7 years IQR (1.1-2.4). The overall attrition rate was 11.8, [95% confidence interval
259 (CI):11.0-12.7] per 100 person years (PY). The other attrition rates are shown in Table 3.

260 **Table 3. Bivariate and multivariate analysis of factors associated with attrition in the 2012-2015 ART cohort**

Variable	Categories	Total	PT years	Attrition [§]	Attrition %	Attrition Per 100PY	HR	p	95%CI	aHR	P	95%CI
Total		3810	6508	768	20.2	11.8						
Sex	Female	2262	3793	440	19.5	11.6	1					
	Male	1548	2689	328	21.2	12.2	1.06	0.4	(0.92 - 1.23)		NS	NS
Age group	Adults	2735	4664	555	20.3	11.9	1			1		
	Children	254	467	35	13.8	7.5	0.62	0.006	(0.44 - 0.87)	0.62	0.007	(0.44 - 0.88)
	Adolescents & young adults	385	563	103	26.8	18.3	1.47	<0.001	(1.19 - 1.82)	1.41	0.002	(1.14 - 1.74)
	Elderly	424	781	75	17.7	9.6	0.81	0.1	(0.64 - 1.04)	0.83	0.1	(0.65 - 1.05)
	Missing	12		0	0.0	0.0						
Marital Status	Married	2125	3612	419	19.7	11.6	1					
	Single & divorced	863	1384	202	23.4	14.6	1.25	0.01	(1.05 - 1.47)			
	Widowed	434	773	85	19.6	11.0	0.97	0.8	(0.76 - 1.22)		NS	NS
	Child N/A	318	583	49	15.4	8.4	0.74	0.4	(0.55 - 0.99)			
	Missing	70	133	13	18.6	9.8	0.88	0.6	(0.51 - 1.53)			
Level of Care	Central & province	1229	2110	230	18.7	10.9	1			1		
	Primary health care facility	1032	1664	213	20.6	12.8	1.15	0.1	(0.96 - 1.39)	1.23	0.04	(1.01 - 1.49)
	District	1549	2708	325	21.0	12.0	1.10	0.2	(0.93 - 1.31)	1.21	0.04	(1.01 - 1.44)
Year ART Initiation	2012-13	1765	4011	377	21.4	9.4	1			1		
	2014-2015	2045	2490	391	19.1	15.7	1.45	<0.001	(1.24 - 1.69)	1.45	<0.001	(1.24 - 1.69)
WHO Stage	I-III	3513	5921	675	19.2	11.4	1			1		
	IV	120	194	43	35.8	22.2	1.95	<0.001	(1.43 - 2.66)	2.06	<0.001	(1.51 - 2.81)
	Missing	177	350	50	28.2	14.3	1.34	0.05	(1.00 - 1.78)	1.52	0.04	(1.02 - 2.27)
Functional status	Normal	2796	4761	538	19.2	11.3	1			1		
	Impaired	811	1321	177	21.8	13.4	1.18	0.06	(0.99 - 1.40)	1.24	0.02	(1.04 - 1.49)
	Missing	203	396	53	26.1	13.4	1.26	0.1	(0.95 - 1.67)	1.01	0.9	(0.69 - 1.50)
Pregnant when starting ART	Not confirmed	3602	6243	718	19.9	11.5	1					
	Confirmed	208	270	50	24.0	18.5	1.48	0.007	(1.12 - 1.98)		NS	NS

NS= Not significant; HR= Hazard Ratio; aHR=adjusted Hazard Ratio; CI= Confidence Interval; ART= Antiretroviral Therapy; WHO= World Health Organisation
[§] either death or LTFU

On bivariate analysis, being an adolescent or a young adult [hazard ratio (HR) 1.47; 95% CI:1.19-1.82], being single or divorced (HR 1.25; 95 CI:1.05-1.47), having initiated ART between 2014-2015 (HR 1.45; 95% CI:1.24-1.69), having WHO Stage 4 (HR 1.95; 95% CI:1.43-2.66) , and being pregnant at time of ART initiation (HR 1.48; 95% CI:1.12-1.98) were associated with attrition ($p < 0.05$). Risk of attrition among children (< 15 years) was 40% lower as compared to adults. In addition, being elderly (HR 0.81; 95%CI:0.64-1.04) and receiving care at PHC facility (HR 1.15; 95%CI:0.96-1.39) were associated at level 0.1 and included in the multivariable regression model.

In multivariable analysis, being an adolescent or a young adult [multivariable-adjusted hazard ratio (aHR)1.41; 95% CI:1.14-1.74], receiving care at PHC facility and district level (aHR 1.23; 95% CI:1.01-1.49) and (aHR 1.21; 95% CI:1.01-1.44), having initiated ART between 2014-2015 (aHR 1.45; 95% CI:1.24-1.69), having WHO Stage 4 (aHR 2.06; 95% CI:1.51-2.81), and having an impaired functional status (aHR1.24; 95% CI:1.04-1.49) were associated with attrition (Table 3).

Discussion

This follow-up evaluation of the Zimbabwe National ART programme, which included children, adolescents and adults started on ART between 2012 and 2015, showed an overall improvement of the performance of the ART programme compared to those started on ART between 2007-2010 [17]. Attrition was mainly explained LTFU. Retention observed in this evaluation was above what is reported for children, adolescents and adults in other similar studies from low resource settings [26–28]. Adolescents and young adults, patients with advanced HIV disease (WHO Stage 4, impaired functional status), those receiving care at PHC level and starting treatment after 2013, when the country switched treatment guidelines to the 500 CD4 cells/mL threshold, were at risk of attrition.

The increase in retention since the previous evaluation may be explained by strategies put in place by the MoHCC. Relying on a vast body of evidence showing that decentralisation increases access to ART and retention in care [29], the prior evaluation recommended further decentralization. Moreover, other innovative strategies to improve patient retention, such as adherence clubs, food supplementation and mobile short messages service (SMS) reminders were recommended [17]. Our data show a substantial increase of the proportion of patients receiving ART at PHC level. This decentralization was supported by policy shifts (in particular, the provision for nurses to initiate ART in non-complicated cases), and by significant investments in training, supportive supervision and clinical mentoring [30]. In addition to decentralisation, the improvement in retention could also be attributed to adoption of WHO guidance for earlier ART initiation among those tested HIV-positive with CD4<500 cells/mL compared to the previous 350 cells/mL CD4 threshold. For instance in this cohort 41.1% had WHO stage 3 or 4 compared to 87.6% in the previous study [17]. However, other recommended measures, such as food supplementation, adherence clubs, mobile short messages service

(SMS) reminders, fast tracking of stable patients on ART, community and family ART refill groups, were not implemented on a wide scale in the public sector.

However, the increase of decentralized ART does probably not explain the higher level of retention, compared to the previous evaluation. Surprisingly, our study showed that receiving ART at PHC level was associated with attrition. This finding contrasts with the findings of the previous evaluation. In the previous evaluation, retention among patients receiving ART at PHC level was better than among those initiating ART at higher levels of care, in particular district/mission hospitals [17]. We speculate that the higher level of attrition in PHC facilities may be explained by the massive decentralisation (down referral), which happened during the current evaluation period, whereby patients who started ART at district/provincial hospitals were referred to PHC level for follow-up. Implementation of policy changes may be abrupt and have an adverse effect. After assessment by a healthcare worker, stable patients may have little or no opportunity to object against the decision to be referred to another clinic. Patients referred to a clinic which is not of their choice are more likely to self-transfer to another facility of their choice. Such patients are then considered as LFTU in one clinic, while retained in another clinic. Moreover, at the beginning of the decentralisation process, care at PHC level may not have been fully developed. Another study showed that abrupt down-referral may lead to a decrease in quality of care and resulting in worse health outcomes [31]. When PHC facilities are ill prepared, usually outcome monitoring is poor. The country has almost completed the decentralisation process for ART services and the focus now should be on improving the quality of care at PHC facilities. The necessary health system support structures which include human resources for health (recruitment, training and capacity building), drug supply, monitoring and evaluation should be prioritised.

Most of the reported attrition (98%) was due to LFTU. This finding was similar to the prior evaluation where LFTU also accounted for the larger proportion of attrition. Determining true LTFU is not always easy. A recent meta-analysis showed that, of patients LTFU and traced, 30% had self-transferred, 30% had stopped taking ART and the other 30% had died [32]. We therefore hypothesize that the increased LTFU in our study might be administrative, especially at PHC level where monitoring is less well developed. A substantial proportion of patients may seem LTFU, but be in care at another or even the same clinic with another identification number [31]. The probability of administrative reasons for LTFU is probably higher at PHC facilities, especially when paper-based tools are used to monitor and report treatment outcomes [31]. Poor documentation of clinic visits and transfers in medical records may result in administrative LTFU. There is need to determine the true nature of the outcome of patients LTFU within the Zimbabwe ART programme. A substantial proportion may be alive and receiving ART from another facility, while others may have died but were not reported as such [33,34]. This may be achieved through strengthening the current active patient tracking and tracing mechanisms [35]. The existing ART programme's electronic patient monitoring systems (ePMS) should also be scaled up and optimised to bring efficiency in patient monitoring [36]. Tracing mechanisms include SMS reminders, phone calls and home visits by community health workers [37].

There was a change in the risk factors for attrition in comparison to the previous evaluation. Males were at risk of attrition in the prior evaluation but were not risk in the current evaluation. Several studies have consistently showed males at high risk of attrition due to several reasons, including employment related constraints and poor health seeking behaviour leading to late presentation [13,15,38]. During the study period the country did not implement many specific interventions that targeted men. Decentralisation of ART services may have also worked in

favour of males for better retention as they could now access services at health facilities closer to where they reside. Another strategy that may have improved male ART uptake and retention was male involvement in PMTCT (Option B+), promoted during massive campaigns [19]. There is a need for further studies to assess whether this strategy suffices, or if other strategies targeting men are needed, such as flexible clinic hours to accommodate work, community-based ART delivery, and tracing of those who miss appointments[39,40].

The previous evaluation did not include data on adolescents and young adults [17]. We found that adolescents and young adults were more at risk of attrition when compared to adults. Our findings are consistent with other studies [41–43]. Adolescents and young adults have been shown to be at high risk of attrition due to several factors, which include lack of youth-friendly services, rigid scheduling not taking into account schooling, and unavailability of peer caregivers [44,45]. Addressing these challenges can lead to improvement in the retention of adolescents and young adults on ART. Locally, community adolescent treatment supporters (CATS) have been shown to improve retention among adolescents and scaling up of the initiative should be prioritised [46].

We found patients with advanced disease to be at higher risk of attrition. Patients with advanced HIV disease are prone to attrition mainly due to mortality and morbidity. The common causes of morbidity and mortality in low resource setting include cryptococcal meningitis, tuberculosis, sepsis, malignancy and wasting syndrome/chronic diarrhoea [47–49]. Advanced HIV disease was also a risk factor for attrition in the previous evaluation. Very minimal investment in building capacity at primary health facilities in the management of patients with advanced HIV disease contributes to poorer outcomes in this subgroup. Indeed, access to baseline CD4 testing, screening and management of opportunistic (tuberculosis, cryptococcal

meningitis) and access to prophylaxis (isoniazid preventive therapy & pre-emptive fluconazole) remains a challenge in the Zimbabwe's public sector [50,51]. Recent evidence has also shown that screening, prophylaxis and management of opportunistic diseases (mainly tuberculosis, bacterial sepsis and cryptococcal disease) significantly reduce morbidity and mortality [52,53]. However, evidence from this enhanced care package is currently being poorly implemented by most ART programmes in low resource setting [54]. There is a need to mobilise resources for training and capacity building of health workers, setting up the necessary infrastructure and procurement of the necessary commodities required in the management of patients with advanced disease. However, the process should be guided by a formal assessment of the current burden of advanced disease in the country.

We also found that patients who started ART after 2013 to be at risk of attrition as compared to those who started prior. We speculate that this could be explained by the fact that patients were now starting ART at a higher CD4 count. In 2013, the country switched ART guidelines to the 500 CD4 cells per cubic millilitres threshold from the 350 cells per cubic millilitres cut-off which was used in 2012. On top of the change in the CD4 cut off point, test and treat was also introduced to specific sub-populations (children under 5 years, TB/HIV co-infected, HBV/HIV co-infected, the HIV-positive partner in HIV sero-discordant relationship and pregnant and breastfeeding mothers (Option B+). Similar findings were reported in previous studies, which showed that patients who started ART at a higher CD4 were at risk of attrition[8,9]. Patients starting ART at high CD4 are less sick and have low risk perception which might affect adherence to long term therapy [55]. This then calls for earnest implementation of the current country operational guidelines which recommends adequate psychosocial preparation and readiness assessment before ART initiation under Treat All [37].

Our study was a follow-up evaluation of the Zimbabwe ART programme. To our knowledge, no studies showing national data have been followed-up by a second study of similar magnitude. In a recent review, none of the studies included was a follow-up to a prior evaluation [5]. Despite the highlighted strengths our study had limitations. Most of the reported attrition was due to LTFU. Patients who are classified as LTFU might have been alive and still on ART (self-transferred), stopped ART or may have died [32]. Our LTFU definition (180 without visit) differed from the one used by the program (LTFU = 90 days late), due to data availability. However, considering that patients received up to 3 months ART refill, both definitions would result in similar findings. Moreover, we could not report on immunologic and virologic patient outcomes due to missing information in the patient manual medical records. Information on viral load testing and CD4 testing was missing.

Conclusion

Zimbabwe's ART program shows good retention across different patient groups. The ART retention increased since the previous 2011 evaluation. However, adolescents and young adults, patients with advanced HIV disease (WHO Stage 4, impaired functional status), receiving care at PHC level and starting treatment after 2013 when the country switched treatment guidelines to the 500 CD4 cells per cubic millilitres threshold were at risk of attrition. From the findings we recommend research into the following areas: reasons for higher attrition at PHC facilities, feasibility of screening for advanced disease at primary health facilities and ensuring access to referral clinical care, assessing retention within levels of care, qualitative research to explore the causal link between attrition in recent years, and being less sick at the start of treatment. To improve monitoring electronic patient monitoring systems should be prioritised to aid patient tracking. There is also a need for differentiated care strategies for adolescents and young adults to improve retention. Creation of youth-friendly services, flexible

scheduling of visits and expansion of peer caregivers/treatment supporters should be considered.

Acknowledgements

The authors of the articles would like express gratitude and appreciation to the following organizations that made immense contributions and technical support to the success of this study namely the Ministry of Health and Child care, National AIDS Council (NAC), University of Zimbabwe College of Health Sciences (UZCHS) Department of Community Medicine, World Health Organization (WHO) and the Institute of Tropical Medicine (ITM), Antwerp, Belgium. The authors would like to appreciate those who participated in training, data abstraction, data cleaning, data entry and regular progress and review meetings during the study: Gerald Shambira, Rosemary Mhlanga-Gunda, Mutsa Mhangara, Angela Mushavi, Amon Mpofu, Brilliant Nkomo, Ngwarai Sithole, Isaac Taramusi, Joseph Murungu, Solomon Mukungunugwa and Christine C. Chakanyuka-Musanhu. We are particularly indebted to the MoHCC management at different levels for the support and permission to enter the respective sampled facilities. Finally, we thank the data abstraction teams, Open Data Kit support team, front line health workers and people living with HIV on ART whose records were reviewed.

Authors Contributions

Author	Contribution
Richard Makurumidze	Conceptualization, Data curation, Formal analysis, Methodology, Validation, Writing – original draft preparation,
Tsitsi Mutasa-Apollo	Conceptualization, Data curation, Methodology, Project administration, Supervision, Writing – review & editing,
Tom Decroo	Conceptualization, Data curation, Validation, Formal analysis, Methodology, Writing – review & editing

Regis C. Choto	Conceptualization, Data curation, Methodology, Project administration, Supervision, Writing – review & editing,
Kudakwashe C. Takarinda	Conceptualization, Data curation, Formal analysis, Methodology, Validation, Writing – review & editing
Janet Dzangare	Conceptualization, Data curation, Formal analysis, Methodology, Validation, Writing – review & editing
Lutgarde Lynen	Conceptualization, Methodology, Writing – review & editing
Wim Van Damme	Conceptualization, Methodology, Writing – review & editing
James Hakim	Conceptualization, Methodology, Writing – review & editing
Tapuwa Magure	Project administration, Supervision, Resources, Funding Acquisition
Owen Mugurungi	Project administration, Supervision, Resources, Funding Acquisition
Simbarashe Rusakaniko	Conceptualization, Data curation, Methodology, Data Analysis, Supervision, Validation, Writing – review & editing

447

448 **Data Availability**

449 The study was conducted with routinely collected data of the Zimbabwe National ART
450 Programme and anonymized individual patient level data. Permission to conduct the study and
451 ethical clearance were obtained from the Ministry of Health & Child Care and the Medical
452 Research Council of Zimbabwe. Permission was also sought to disseminate the results in
453 relevant scientific forums. However, the data which was used to conduct is not available on the
454 public domain and anyone interested in using the data for scientific purpose is free to request
455 permission from the Director of the AIDS and TB Program, Dr Owen Mugurungi, Director of
456 the AIDS and TB Program, AIDS and TB Unit, Ministry of Health and Child Care,
457 Government of Zimbabwe, 2nd Floor, Mukwati Building, Harare, Zimbabwe. E-mail:
458 atp.director@ymail.com

459 **Funding**

The study was supported with funding from the Global Fund for AIDS, Tuberculosis, and Malaria (GFATM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Richard Makurumidze receives a PhD scholarship grant from the Institute of Tropical Medicine, funded by the Belgian Development Cooperation.

Competing Interests

The authors declare that they have no competing interests.

References

1. The Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2019. 2019.
2. The Joint United Nations Programme on AIDS (UNAIDS). Global HIV & AIDS statistics — 2019 fact sheet [Internet]. 2019. Available: <https://www.unaids.org/en/resources/fact-sheet>
3. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. *BMJ Glob Heal*. 2016;1: e000010. doi:10.1136/bmjgh-2015-000010
4. Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. *Patient Prefer Adherence*. 2019;Volume 13: 475–490. doi:10.2147/PPA.S192735
5. Bulsara SM, Wainberg ML, Newton-John TRO. Predictors of Adult Retention in HIV

- 482 Care: A Systematic Review. *AIDS Behav.* 2018;22: 752–764. doi:10.1007/s10461-
483 016-1644-y
- 484 6. Ugoji C, Okere N, Dakum P, Ake-uzoigwe R, Igboelina D, Ndembu N, et al. Correlates
485 of Patient Retention in HIV Care and Treatment Programs in Nigeria. *Curr HIV Res.*
486 2015; 300–307.
- 487 7. Janssen S, Wieten RW, Stolp S, Cremers AL, Rossatanga EG, Klipstein-Grobusch K,
488 et al. Factors Associated with Retention to Care in an HIV Clinic in Gabon, Central
489 Africa. *PLoS One.* 2015;10: e0140746. doi:10.1371/journal.pone.0140746
- 490 8. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, Ele P, et al. Patient Retention
491 and Adherence to Antiretrovirals in a Large Antiretroviral Therapy Program in
492 Nigeria: A Longitudinal Analysis for Risk Factors. *PLoS One.* 2010;5: e10584.
493 doi:10.1371/journal.pone.0010584
- 494 9. Stafford KA, Odafe SF, Lo J, Ibrahim R, Ehoche A, Niyang M, et al. Evaluation of the
495 clinical outcomes of the Test and Treat strategy to implement Treat All in Nigeria:
496 Results from the Nigeria Multi-Center ART Study. *PLoS One.* 2019;14: e0218555.
497 doi:10.1371/journal.pone.0218555
- 498 10. Arnesen R, Moll AP, Sheno S V. Predictors of loss to follow-up among patients on
499 ART at a rural hospital in KwaZulu-Natal, South Africa. *PLoS One.* 2017;12:
500 e0177168. doi:10.1371/journal.pone.0177168
- 501 11. Tiruneh YM, Galárraga O, Genberg B, Wilson IB. Retention in Care among HIV-
502 Infected Adults in Ethiopia, 2005– 2011: A Mixed-Methods Study. *PLoS One.*
503 2016;11: e0156619. doi:10.1371/journal.pone.0156619
- 504 12. Shamu T, Chimbetete C, Shawarira–Bote S, Mudzviti T, Luthy R. Outcomes of an

- 505 HIV cohort after a decade of comprehensive care at Newlands Clinic in Harare,
506 Zimbabwe: TENART cohort. PLoS One. 2017;12: e0186726.
507 doi:10.1371/journal.pone.0186726
- 508 13. Auld AF, Ekra KA, Shiraishi RW, Tuho MZ, Kouakou JS, Mohamed F, et al.
509 Temporal Trends in Treatment Outcomes for HIV-1 and HIV-2-Infected Adults
510 Enrolled in Côte d'Ivoire's National Antiretroviral Therapy Program. PLoS One.
511 2014;9: e98183. doi:10.1371/journal.pone.0098183
- 512 14. Auld AF, Alfredo C, Macassa E, Jobarteh K, Shiraishi RW, Rivadeneira ED, et al.
513 Temporal Trends in Patient Characteristics and Outcomes Among Children Enrolled in
514 Mozambique's National Antiretroviral Therapy Program. Pediatr Infect Dis J.
515 2015;34: e191–e199. doi:10.1097/INF.0000000000000741
- 516 15. Dalhatu I, Onotu D, Odafe S, Abiri O, Debem H, Agolory S, et al. Outcomes of
517 Nigeria's HIV/AIDS Treatment Program for Patients Initiated on Antiretroviral
518 Treatment between 2004-2012. PLoS One. 2016;11: e0165528.
519 doi:10.1371/journal.pone.0165528
- 520 16. Nabukeera-Barungi N, Elyanu P, Asire B, Katureebe C, Lukabwe I, Namusoke E, et
521 al. Adherence to antiretroviral therapy and retention in care for adolescents living with
522 HIV from 10 districts in Uganda. BMC Infect Dis. 2015;15: 520. doi:10.1186/s12879-
523 015-1265-5
- 524 17. Mutasa-Apollo T, Shiraishi RW, Takarinda KC, Dzangare J, Mugurungi O, Murungu
525 J, et al. Patient Retention, Clinical Outcomes and Attrition-Associated Factors of HIV-
526 Infected Patients Enrolled in Zimbabwe's National Antiretroviral Therapy Programme,
527 2007–2010. PLoS One. 2014;9: e86305. doi:10.1371/journal.pone.0086305

- 528 18. Ministry of Health and Child Care (MoHCC). Zimbabwe ART Annual Report. 2018.
- 529 19. Tlhajoane M, Masoka T, Mpandaguta E, Rhead R, Church K, Wringe A, et al. A
530 longitudinal review of national HIV policy and progress made in health facility
531 implementation in Eastern Zimbabwe. Heal Res Policy Syst. 2018;16: 92.
532 doi:10.1186/s12961-018-0358-1
- 533 20. Zimbabwe National Statistics Agency (ZIMSTAT). Zimbabwe National Census
534 Report. Harare, Zimbabwe; 2012.
- 535 21. ICAP at Columbia University. Zimbabwe Population Based HIV Impact Assessment
536 Preliminary Report. 2016.
- 537 22. National AIDS Council of Zimbabwe (NAC). Zimbabwe National HIV and AIDS
538 Strategic Plan (ZNASP II) 2011 - 2015. 2011;
- 539 23. Ministry of Health and Child Care (MoHCC). Zimbabwe ART Annual Report. 2015.
- 540 24. Ministry of Health and Child Care(MoHCC). An Evaluation of the Use of Point of
541 CarePIMA CD4 Cell Count Machines for HIV Positive Women and their Families in
542 Maternal Newborn And Child Health (MNCH) Settings in Seven Districts in
543 Zimbabwe. 2012;
- 544 25. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP.;
545 2015.
- 546 26. Murray KR, Dulli LS, Ridgeway K, Dal Santo L, Darrow de Mora D, Olsen P, et al.
547 Improving retention in HIV care among adolescents and adults in low- and middle-
548 income countries: A systematic review of the literature. PLoS One. 2017;12:
549 e0184879. doi:10.1371/journal.pone.0184879

- 550 27. Fox MP, Rosen S. Systematic review of retention of pediatric patients on HIV
551 treatment in low and middle-income countries 2008–2013. *AIDS*. 2015;29: 493–502.
552 doi:10.1097/QAD.0000000000000559
- 553 28. Fox MP, Rosen S. Retention of Adult Patients on Antiretroviral Therapy in Low- and
554 Middle-Income Countries. *JAIDS J Acquir Immune Defic Syndr*. 2015;69: 98–108.
555 doi:10.1097/QAI.0000000000000553
- 556 29. Kredo T, Ford N, Adeniyi FB, Garner P. Decentralising HIV treatment in lower- and
557 middle-income countries. *Cochrane Database Syst Rev*. 2013;132: 383.
558 doi:10.1002/14651858.CD009987.pub2
- 559 30. Ministry of Health and Child Care (MoHCC). ART Outcomes of People Living with
560 HIV Enrolled in the National ART Programme, Zimbabwe, October 2012 – January
561 2015 - Technical Report. 2016.
- 562 31. Decroo T, Panunzi I, das Dores C, Maldonado F, Biot M, Ford N, et al. Lessons
563 learned during down referral of antiretroviral treatment in Tete, Mozambique. *J Int*
564 *AIDS Soc*. 2009;12: 6. doi:10.1186/1758-2652-12-6
- 565 32. Zürcher K, Mooser A, Anderegg N, Tymejczyk O, Couvillon MJ, Nash D, et al.
566 Outcomes of HIV-positive patients lost to follow-up in African treatment programmes.
567 *Trop Med Int Heal*. 2017;22: 375–387. doi:10.1111/tmi.12843
- 568 33. Wilkinson LS, Skordis-Worrall J, Ajose O, Ford N. Self-transfer and mortality
569 amongst adults lost to follow-up in ART programmes in low- and middle-income
570 countries: systematic review and meta-analysis. *Trop Med Int Heal*. 2015;20: 365–379.
571 doi:10.1111/tmi.12434
- 572 34. Cornell M, Lessells R, Fox MP, Garone DB, Giddy J, Fenner L, et al. Mortality

Among Adults Transferred and Lost to Follow-up From Antiretroviral Therapy
Programmes in South Africa. JAIDS J Acquir Immune Defic Syndr. 2014;67: e67–
e75. doi:10.1097/QAI.0000000000000269

35. United States of America President’s Emergency Plan for AIDS Relief (PEPFAR).
Loss to Follow-Up Tool: Tracking and Tracing HIV Patients [Internet]. PEPFAR Beta
Solutions; 2019. Available: [https://www.pepfarsolutions.org/tools-2/2019/1/4/loss-to-](https://www.pepfarsolutions.org/tools-2/2019/1/4/loss-to-follow-up-tool)
follow-up-tool

36. Egger M. Electronic medical record systems, data quality and loss to follow-up: survey
of antiretroviral therapy programmes in resource-limited settings. Bull World Health
Organ. 2008;86: 939–947. doi:10.2471/BLT.07.049908

37. Ministry of Health and Child Care Zimbabwe (MoHCC). Operations and Service
delivery manual for the Prevention, Care and Treatment of HIV in Zimbabwe. Harare.
2015;

38. Mills EJ, Beyrer C, Birungi J, Dybul MR. Engaging Men in Prevention and Care for
HIV/AIDS in Africa. PLoS Med. 2012;9: e1001167.
doi:10.1371/journal.pmed.1001167

39. Koole O, Tsui S, Wabwire-Mangen F, Kwesigabo G, Menten J, Mulenga M, et al.
Retention and risk factors for attrition among adults in antiretroviral treatment
programmes in Tanzania, Uganda and Zambia. Trop Med Int Heal. 2014;19: 1397–
1410. doi:10.1111/tmi.12386

40. Brown LB, Getahun M, Ayieko J, Kwarisiima D, Owaraganise A, Atukunda M, et al.
Factors predictive of successful retention in care among HIV-infected men in a
universal test-and-treat setting in Uganda and Kenya: A mixed methods analysis. PLoS

- 596 One. 2019;14: e0210126. doi:10.1371/journal.pone.0210126
- 597 41. Ferrand RA. Attrition from HIV care among adolescents and adults in a low-income
598 setting. Public Heal Action. 2016;6: 53–53. doi:10.5588/pha.16.0035
- 599 42. Matyanga CMJ, Takarinda KC, Owiti P, Mutasa-Apollo T, Mugurungi O, Buruwe L,
600 et al. Outcomes of antiretroviral therapy among younger versus older adolescents and
601 adults in an urban clinic, Zimbabwe. Public Heal Action. 2016;6: 97–104.
602 doi:10.5588/pha.15.0077
- 603 43. Evans D, Menezes C, Mahomed K, Macdonald P, Untiedt S, Levin L, et al. Treatment
604 Outcomes of HIV-Infected Adolescents Attending Public-Sector HIV Clinics Across
605 Gauteng and Mpumalanga, South Africa. AIDS Res Hum Retroviruses. 2013;29: 892–
606 900. doi:10.1089/aid.2012.0215
- 607 44. Zanoni BC, Sibaya T, Cairns C, Haberer JE. Barriers to Retention in Care are
608 Overcome by Adolescent-Friendly Services for Adolescents Living with HIV in South
609 Africa: A Qualitative Analysis. AIDS Behav. 2019;23: 957–965. doi:10.1007/s10461-
610 018-2352-6
- 611 45. Murray KR, Dulli LS, Ridgeway K, Dal Santo L, Darrow de Mora D, Olsen P, et al.
612 Improving retention in HIV care among adolescents and adults in low- and middle-
613 income countries: A systematic review of the literature. PLoS One. 2017;12:
614 e0184879. doi:10.1371/journal.pone.0184879
- 615 46. Willis N, Milanzi A, Mawodzeke M, Dziwa C, Armstrong A, Yekeye I, et al.
616 Effectiveness of community adolescent treatment supporters (CATS) interventions in
617 improving linkage and retention in care, adherence to ART and psychosocial well-
618 being: a randomised trial among adolescents living with HIV in rural Zimbabwe. BMC

- 619 Public Health. 2019;19: 117. doi:10.1186/s12889-019-6447-4
- 620 47. Harries AD, Zachariah R, Lawn SD, Rosen S. Strategies to improve patient retention
621 on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Heal. 2010;15: 70–75.
622 doi:10.1111/j.1365-3156.2010.02506.x
- 623 48. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in
624 adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV
625 AIDS. 2010;5: 18–26. doi:10.1097/COH.0b013e328333850f
- 626 49. Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, Ceffa S, et al. Excessive
627 Early Mortality in the First Year of Treatment in HIV Type 1-Infected Patients
628 Initiating Antiretroviral Therapy in Resource-Limited Settings. AIDS Res Hum
629 Retroviruses. 2008;24: 555–560. doi:10.1089/aid.2007.0217
- 630 50. Takarinda KC, Choto RC, Mutasa-Apollo T, Chakanyuka-Musanhu C, Timire C,
631 Harries AD. Scaling up isoniazid preventive therapy in Zimbabwe: has operational
632 research influenced policy and practice? Public Heal Action. 2018;8: 218–224.
633 doi:10.5588/pha.18.0051
- 634 51. Gonese G, Bochner AF, Makurumidze R, Apollo T, Makunike B, Meacham E, et al.
635 Challenges in Managing Cryptococcal Meningitis in Resource-Limited Settings : A
636 Baseline Assessment. Abstr Accept Poster Present Int AIDS Conf 23 - 26 July 2017.
637 2017;
- 638 52. Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V, et al.
639 Cryptococcal meningitis screening and community-based early adherence support in
640 people with advanced HIV infection starting antiretroviral therapy in Tanzania and
641 Zambia: An open-label, randomised controlled trial. Lancet. 2015;385: 2173–2182.

doi:10.1016/S0140-6736(15)60164-7

53. Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, et al. Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa. *N Engl J Med*. 2017;377: 233–245. doi:10.1056/NEJMoa1615822
54. Benzekri NA, Sambou JF, Ndong S, Tamba IT, Faye D, Diallo MB, et al. Prevalence, predictors, and management of advanced HIV disease among individuals initiating ART in Senegal, West Africa. *BMC Infect Dis*. 2019;19: 261. doi:10.1186/s12879-019-3826-5
55. Bigna JJR, Plottel CS, Koulla-shiro S. Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count. *Infect Dis Poverty*. 2016; 1–6. doi:10.1186/s40249-016-0179-9

Targeted number of records to be abstracted

4000

7 records were not reviewed

Actual number records abstracted

3993


183 records dropped

- Patients enrolled before 1 October 2012
- Patients enrolled after 31 January 2015
- ART start date missing
- Last visit/outcome date missing
- Patients in care for less than 6 months


Number of records finally analysed

3810

Figure



Figure



Figure